Today: 9 June 2026
Circle Internet Group stock price: CRCL slips premarket after earnings surge, rate bets bite
27 February 2026
2 mins read

Circle Internet Group stock price: CRCL slips premarket after earnings surge, rate bets bite

NEW YORK, Feb 27, 2026, 08:13 ET — Premarket

  • Circle shares pulled back in premarket trading, giving up some ground after their strong, earnings-fueled surge.
  • The direction of USDC and where U.S. rates head next are shaping the conversation.
  • March 6 brings the next macro hurdle for rate-sensitive names: the U.S. jobs report.

Circle Internet Group (CRCL.N) slipped 2.9% to $84.70 before the bell Friday, pulling back after a 4.9% jump to $87.21 in the previous session.

Investors are working through Circle’s latest quarterly results, which topped forecasts and shed light on demand for USDC, the company’s dollar-linked stablecoin backed by cash and low-risk assets. Circle’s business is notably exposed to U.S. rate moves, since it earns reserve income on USDC’s backing. CEO Jeremy Allaire told Reuters that “further cuts this year are ‘welcome’.” Seaport Research Partners’ Jeff Cantwell pointed out, “USDC continues scaling rapidly.” Reuters

Circle reported USDC circulation reaching $75.3 billion at the close of 2025, a 72% jump from the year before. Fourth-quarter total revenue and reserve income climbed 77% to $770 million, with net income from continuing operations at $133 million. For 2026, the company projects “other revenue” between $150 million and $170 million. Arc, Circle’s upcoming layer-1 blockchain meant to serve as the backbone for new on-chain applications, is averaging 2.3 million daily transactions in testnet. The Circle Payments Network, for its part, has 55 financial institutions enrolled. “The fourth quarter marked another step forward” toward an “open, programmable internet financial system,” Allaire said in the earnings release. SEC

Needham dropped its price target on Circle to $130 from $190 but stuck with a Buy, pointing to revised interest-rate expectations and recent crypto price weakness, both of which could slow USDC supply growth. Still, the firm flagged potential in on-chain micropayments — think AI agents making frequent, tiny payments — and the ongoing move to tokenization, where real-world assets are turned into digital tokens on the blockchain.

Morgan Stanley bumped its price target up to $80 from $66 while sticking with its Equalweight rating. The firm pointed to quicker gains in non-reserve revenue, like the payments network, as a possible boost for earnings down the line. Valuation? They’re using a 25-times earnings multiple, lining it up with longer-term averages at Visa and Mastercard.

Circle’s surge this week is spotlighting the tension in its business: rising short-term rates fatten reserve income, yet the firm maintains that falling rates might kick up activity by making money move faster and fueling demand for digital dollars.

But stablecoin expansion isn’t guaranteed. If crypto markets sink further, that could choke off activity and stall new USDC inflows. Plus, Tether and other heavyweight competitors are keeping the squeeze on both pricing and distribution.

Traders are eyeing Circle’s attempts to expand revenue beyond reserve income, looking for signs of early traction in run-rate figures linked to payments, transactions, and fresh infrastructure offerings.

Traders are watching Friday, March 6: the U.S. February jobs numbers land then, and expectations are set at a modest 60,000 payroll gain, according to a Reuters poll. That figure could end up realigning bets on when the Federal Reserve moves to cut rates.

Stock Market Today

  • Broadcom Stock Set for 27% Gain to $500 Amid AI Growth, Despite Recent Selloff
    June 9, 2026, 10:08 AM EDT. Broadcom (NASDAQ:AVGO) shares dropped nearly 14% post-earnings despite 47.87% revenue growth and an eighth straight earnings per share (EPS) beat. The stock trades around $396.60, with a 24/7 Wall St. price target of $503.61, implying a 26.98% upside over 12 months and a buy recommendation at 90% confidence. Broadcom's Q2 revenue hit $22.19 billion with a 143% jump in AI semiconductor sales to $10.8 billion. CEO Hock Tan projects over 200% AI revenue growth in Q3, targeting $16 billion. Bear risks include heavy insider selling and a high 64 forward P/E ratio. Bulls note strong AI demand, with price targets up to $600 billion revenue potential by 2028. The stock remains 14.82% higher year-to-date despite recent volatility.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal
Previous Story

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

CBA’s $1 Billion Mortgage Fraud Alarm: Big Banks Face New AI-Document Threat
Next Story

CBA’s $1 Billion Mortgage Fraud Alarm: Big Banks Face New AI-Document Threat

Go toTop